MedImmune to Sell CytoGam(R) to ZLB Behring
2006年11月9日 - 7:15AM
PRニュース・ワイアー (英語)
GAITHERSBURG, Md., Nov. 8 /PRNewswire-FirstCall/ -- MedImmune, Inc.
(NASDAQ:MEDI) today announced its intent to sell CytoGam(R)
(cytomegalovirus immune globulin intravenous (human)) to ZLB
Behring. Under the terms of a definitive agreement, ZLB Behring
will make a one-time upfront payment of $50 million to MedImmune,
plus equipment and inventory payments, for full worldwide rights to
CytoGam. Further, an additional $70 million may be paid to
MedImmune by ZLB Behring upon achievement of certain cumulative net
sales milestones. CytoGam is an intravenous immune globulin
enriched in antibodies against cytomegalovirus (CMV). It is used to
prevent CMV disease associated with transplantation of the kidney,
lung, liver, pancreas and heart. "CytoGam was the first product
commercialized by MedImmune beginning in 1992. It has been an
important product for transplant patients as well as for the
development of our company. However, CytoGam no longer fits into
our core areas of focus," said David M. Mott, MedImmune's president
and chief executive officer. Mr. Mott continued, "CytoGam is an
excellent fit for ZLB Behring and their portfolio of plasma-derived
therapies, and we believe they will do an outstanding job of
ensuring that CytoGam continues to meet an important need for organ
transplant patients. MedImmune intends to redeploy the proceeds
from the sale of CytoGam into areas consistent with our strategic
focus on the development of novel, proprietary products for
infectious diseases, cancer and inflammatory diseases." Peter
Turner, president of ZLB Behring, stated: "The addition of CytoGam
strengthens ZLB Behring's immunoglobulin portfolio and supports the
company's mission to provide a reliable, quality supply of critical
therapies to small patient populations. We are pleased to continue
advancing that mission by addressing important medical needs of
transplant patients." MedImmune and ZLB Behring expect the
transaction to be completed in approximately 30 days, subject to
fulfillment of customary closing conditions, including any
necessary governmental approval. Impact to MedImmune's 2006
Financial Guidance The estimated 2006 financial impact of the
CytoGam transaction is an increase in diluted earnings per share of
$0.10 to $0.12, primarily due to the one-time upfront payment of
$50 million, assuming receipt of necessary government approval in
time to consummate the transaction before the end of the year.
However, the impact of this transaction may be partially to fully
offset by other in-process business transactions that have the
potential to be successfully completed by the end of 2006.
Therefore, MedImmune has chosen not to revise its previously stated
earnings guidance range of $0.17 to $0.22 per diluted share, before
stock compensation expense, at this time. About CytoGam CytoGam is
indicated for the prophylaxis of cytomegalovirus disease associated
with transplantation of kidney, lung, liver, pancreas and heart. In
transplants of these organs other than kidney from CMV seropositive
donors into seronegative recipients, prophylactic CMV-IGIV should
be considered in combination with ganciclovir. CytoGam is made from
human plasma and like other plasma products carries the possibility
for transmission of blood-borne viral agents. CytoGam should not be
used in individuals with a history of a prior severe reaction to
CytoGam or other human immunoglobulins. Immune Globulin Intravenous
(Human) products have been reported to be associated with renal
dysfunction, acute renal failure, osmotic nephrosis, and death.
CytoGam contains sucrose as a stabilizer. In patients predisposed
to acute renal failure, IGIV products should be administered at the
minimum concentrations available and the minimum rate of infusion
practical. Severe reactions such as angioneurotic edema and
anaphylactic shock, although not observed during clinical trials,
are a possibility. Minor reactions such as flushing, chills, muscle
cramps, back pain, fever, nausea, vomiting, arthralgia, and
wheezing were the most frequent adverse reactions observed during
clinical trials. For more information, please download a package
insert at http://www.medimmune.com/pdf/products/cytogam_pi.pdf.
About MedImmune, Inc. MedImmune strives to provide better medicines
to patients, new medical options for physicians, rewarding careers
to employees, and increased value to shareholders. Dedicated to
advancing science and medicine to help people live better lives,
the company is focused on the areas of infectious diseases, cancer
and inflammatory diseases. With more than 2,500 employees
worldwide, MedImmune is headquartered in Maryland. For more
information, visit the company's website at
http://www.medimmune.com/. About ZLB Behring ZLB Behring is a
global leader in the plasma protein biotherapeutics industry.
Dedicated to improving the quality of life for patients throughout
the world, ZLB Behring provides safe and effective plasma-derived
and recombinant products and offers patients a wide range of
related services. The company's broad portfolio of life-saving
therapeutics are used in the treatment of individuals with
hemophilia, von Willebrand Disease and other bleeding disorders,
immune deficiency disorders and inherited emphysema; the prevention
of hemolytic diseases for the newborn; cardiac surgery patients;
and shock and burn victims. Additionally, ZLB Behring operates one
of the world's largest, fully-owned plasma collection networks. ZLB
Behring is a subsidiary of CSL Limited, a biopharmaceutical
company, which operates worldwide from its headquarters in
Melbourne, Australia. For more information about the company,
please visit http://www.zlbbehring.com/. This announcement may
contain, in addition to historical information, certain
forward-looking statements that involve risks and uncertainties.
Such statements reflect management's current views and are based on
certain assumptions. Actual results could differ materially from
those currently anticipated as a result of a number of factors,
including risks and uncertainties discussed in MedImmune's filings
with the Securities and Exchange Commission. Consummation of this
transaction requires fulfillment of certain conditions and
accordingly, there can be no assurance that the proposed
divestiture will close or will be completed without unanticipated
costs. DATASOURCE: MedImmune, Inc. CONTACT: Media: Kate Barrett,
+1-301-398-4320, or Investors: Peter Vozzo, +1-301-398-4358, both
of MedImmune, Inc. Web site: http://www.medimmune.com/
http://www.zlbbehring.com/
Copyright
Medimmune (NASDAQ:MEDI)
過去 株価チャート
から 11 2024 まで 12 2024
Medimmune (NASDAQ:MEDI)
過去 株価チャート
から 12 2023 まで 12 2024